缬沙坦联合胰激肽原酶治疗早期糖尿病肾病的疗效观察

摘要

Objective To observe the therapeutic effect of the combined kallidinogenase and valsartan on early stage of type 2 diabetic nephropathy.Methods The 90 study subjects were randomly divided into three groups of observation group (valsartan plus kallidinagenase, n = 30), ARB group (valsartan,n=30) and control group(n= 30).After 6 months of treatments the patients underwent examinations of urinary albumin excretion rate (UAER), urine β2-microglobulin (β2-MG) , mean arterial blood pressure (MAP), serum creatinine (Scr) and hemoglobin Alc (HbA1 c).Results The values of UAER and β2-MG had obviously decrease after treatment and were lower in observation and ARB group than was control group (P＜0.01) and were lower in observation than in ARB group.The MAP of the three groups significantly decreased as compared to the baseline,with no differences among three groups (P＞0.05).Conclusion The combined valsartan and kallidinogenase treatment have good effects in the treatment of early stage of type 2 diabetic nephropathy with lessening the abnormal urinary albumin.%目的 观察缬沙坦联合胰激肽原酶治疗早期糖尿病肾病(DN)的临床疗效.方法 90例早期DN患者随机分成3组,缬沙坦联合胰激肽原酶组、缬沙坦组及对照组各30例,观察6个月,比较治疗前后患者尿白蛋白排泄率(UAER)、尿β2-微球蛋白(β2-GM)、平均动脉压(MAP)、血清肌肝(Scr)及糖化血红蛋白(HbA1c)变化.结果:治疗后缬沙坦联合胰激肽原酶组及缬沙坦组UAER及尿β2-MG较治疗前显著下降(P<0.01),且较对照组显著下降(P<0.01),缬沙坦联合胰激肽原酶组较缬沙坦组下降更为显著(P<0.01),3组治疗后MAP较治疗前均有明显下降(P<0.01),3组之间无统计学差异(P>0.05).结论 缬沙坦联合胰激肽原酶治疗早期DN疗效确切,可有效减轻糖尿病肾病患者白蛋白尿.